{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:50:50Z","timestamp":1781949050233,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004473","name":"Sakarya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004473","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Pathological upgrading is common in men with ISUP Grade Group (GG) 1 prostate cancer due to sampling limitations.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT is promising for characterizing tumor biology. The 5-point PRIMARY score, which considers uptake, focality, and location, has limited data on predicting occult high-grade cancer in GG1 biopsy patients. This study assessed the score\u2019s accuracy in predicting upgrading in GG1 prostate cancer patients with PSA\u2009&lt;\u200920 ng\/mL undergoing radical prostatectomy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 71 patients with biopsy-proven GG1 prostate adenocarcinoma, PSA &lt; 20 ng\/mL, and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT performed within 2 months before radical prostatectomy. PRIMARY scores [1\u20135] were assigned by two blinded nuclear medicine physicians; scores \u2265 4 were considered high-risk. Pathological upgrading was defined as ISUP GG \u2265 2 on prostatectomy specimens. Diagnostic performance was assessed using ROC analysis, and univariate and multivariate logistic regression models were constructed to determine independent predictors of upgrading.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pathological upgrading occurred in 45\/71 patients (63.4%). Upgrading rates increased markedly across PRIMARY score categories: 25% for scores\u2009\u2264\u20093, 81.3% for score 4, and 100% for score 5 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). A PRIMARY score\u2009\u2265\u20094 demonstrated excellent diagnostic performance (AUC\u2009=\u20090.979), with 97.8% sensitivity, 88.5% specificity, 93.6% PPV, 95.6% NPV, and 94.3% accuracy. SUVmax (AUC\u2009=\u20090.944) and PI-RADS\u2009\u2265\u20094 (AUC\u2009=\u20090.721) were also associated with upgrading; however, in multivariate analysis, only the PRIMARY score remained an independent predictor (OR: 19.9; 95% CI: 2.92-135.28;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      \u201cThe\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA-11 PET\/CT PRIMARY score was strongly associated with pathological upgrading in this surgically treated cohort of biopsy-confirmed ISUP GG1 patients with PSA\u2009&lt;\u200920 ng\/mL undergoing radical prostatectomy. Incorporating PSMA-based intraprostatic pattern analysis could improve the accuracy of preoperative grading, potentially supporting consideration of surgical management rather than definitive radiotherapy when determining the optimal treatment strategy. Prospective multicenter validation is warranted before broader clinical implementation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-026-02179-z","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:33:40Z","timestamp":1772516020000},"page":"746-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive value of the 68Ga-PSMA-11 PET\/CT PRIMARY score for pathological upgrading in patients with ISUP Grade 1 prostate cancer and PSA\u2009&lt;\u200920 ng\/mL undergoing radical prostatectomy"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6106-7733","authenticated-orcid":false,"given":"Esra","family":"Ciftci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-0839","authenticated-orcid":false,"given":"Burak","family":"Akovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6410-0746","authenticated-orcid":false,"given":"Hatice Sariyildiz","family":"Gumusgoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-0936","authenticated-orcid":false,"given":"Burcin Karasah","family":"Erkek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2179_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209\u201349.","DOI":"10.3322\/caac.21660"},{"issue":"1","key":"2179_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.euo.2019.08.001","volume":"3","author":"S Goel","year":"2020","unstructured":"Goel S, Shoag JE, Gross MD, Al Hussein Al Awamlh B, Robinson B, Khani F, et al. Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020;3(1):10\u201320.","journal-title":"Eur Urol Oncol"},{"issue":"10","key":"2179_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2179_CR4","first-page":"Cd012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4(4):Cd012663.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2179_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"issue":"11","key":"2179_CR6","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET\/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63(11):1644\u201350.","journal-title":"J Nucl Med"},{"issue":"4","key":"2179_CR7","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1007\/s00330-024-11062-2","volume":"35","author":"M Boschheidgen","year":"2025","unstructured":"Boschheidgen M, Schimm\u00f6ller L, Radtke JP, Kastl R, Jannusch K, Lakes J, et al. MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer. Eur Radiol. 2025;35(4):2170\u20139.","journal-title":"Eur Radiol"},{"issue":"7","key":"2179_CR8","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.1002\/bco2.70043","volume":"6","author":"Z Pan","year":"2025","unstructured":"Pan Z, Zhao R, Fan J, Zhang S, Li J, Liu B. ISUP grade upgrade prediction after radical prostatectomy: Role of Luteinizing Hormone to Testosterone ratio. BJUI Compass. 2025;6(7):e70043.","journal-title":"BJUI Compass"},{"issue":"1","key":"2179_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","volume":"65","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, et al. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med. 2024;65(1):94\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"2179_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/pros.24621","volume":"84","author":"B Esen","year":"2024","unstructured":"Esen B, Seymen H, Gurses B, Armutlu A, Koseoglu E, Tarim K, et al. The role of PSMA PET\/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer. Prostate. 2024;84(1):32\u20138.","journal-title":"Prostate"},{"issue":"1","key":"2179_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s00259-024-06847-y","volume":"52","author":"TFW Soeterik","year":"2024","unstructured":"Soeterik TFW, Heetman JG, Hermsen R, Wever L, Lavalaye J, Vinken M, et al. The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis. Eur J Nucl Med Mol Imaging. 2024;52(1):314\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2179_CR12","first-page":"11955","volume":"31","author":"S Dekalo","year":"2024","unstructured":"Dekalo S, Mazliah O, Barkai E, Bar-Yosef Y, Herzberg H, Bashi T, et al. MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer. Can J Urol. 2024;31(4):11955\u201362.","journal-title":"Can J Urol"},{"issue":"5","key":"2179_CR13","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-023-06556-y","volume":"51","author":"K Akcay","year":"2024","unstructured":"Akcay K, Kibar A, Sahin OE, Demirbilek M, Beydagi G, Asa S, et al. Prediction of clinically significant prostate cancer by [68 Ga]Ga-PSMA-11 PET\/CT: a potential tool for selecting patients for active surveillance. Eur J Nucl Med Mol Imaging. 2024;51(5):1467\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2179_CR14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s00259-024-06642-9","volume":"51","author":"L Kabasakal","year":"2024","unstructured":"Kabasakal L, Turkay R, Onal B. Incorporating the [68Ga]Ga-PSMA PET\/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance. Eur J Nucl Med Mol Imaging. 2024;51(5):1464\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2179_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021;80(6):682\u20139.","journal-title":"Eur Urol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02179-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02179-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02179-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:10:27Z","timestamp":1781946627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02179-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2179"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02179-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}